Cargando…
Oral submucous fibrosis: an update
Oral submucous fibrosis (OSF) is a premalignant condition caused by betel chewing. It is very common in Southeast Asia but has started to spread to Europe and North America. OSF can lead to squamous cell carcinoma, a risk that is further increased by concomitant tobacco consumption. OSF is a diagnos...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401336/ https://www.ncbi.nlm.nih.gov/pubmed/25914554 http://dx.doi.org/10.2147/CCID.S80576 |
_version_ | 1782367134503927808 |
---|---|
author | Wollina, Uwe Verma, Shyam B Ali, Fareedi Mukram Patil, Kishor |
author_facet | Wollina, Uwe Verma, Shyam B Ali, Fareedi Mukram Patil, Kishor |
author_sort | Wollina, Uwe |
collection | PubMed |
description | Oral submucous fibrosis (OSF) is a premalignant condition caused by betel chewing. It is very common in Southeast Asia but has started to spread to Europe and North America. OSF can lead to squamous cell carcinoma, a risk that is further increased by concomitant tobacco consumption. OSF is a diagnosis based on clinical symptoms and confirmation by histopathology. Hypovascularity leading to blanching of the oral mucosa, staining of teeth and gingiva, and trismus are major symptoms. Major constituents of betel quid are arecoline from betel nuts and copper, which are responsible for fibroblast dysfunction and fibrosis. A variety of extracellular and intracellular signaling pathways might be involved. Treatment of OSF is difficult, as not many large, randomized controlled trials have been conducted. The principal actions of drug therapy include antifibrotic, anti-inflammatory, and antioxygen radical mechanisms. Potential new drugs are on the horizon. Surgery may be necessary in advanced cases of trismus. Prevention is most important, as no healing can be achieved with available treatments. |
format | Online Article Text |
id | pubmed-4401336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-44013362015-04-24 Oral submucous fibrosis: an update Wollina, Uwe Verma, Shyam B Ali, Fareedi Mukram Patil, Kishor Clin Cosmet Investig Dermatol Review Oral submucous fibrosis (OSF) is a premalignant condition caused by betel chewing. It is very common in Southeast Asia but has started to spread to Europe and North America. OSF can lead to squamous cell carcinoma, a risk that is further increased by concomitant tobacco consumption. OSF is a diagnosis based on clinical symptoms and confirmation by histopathology. Hypovascularity leading to blanching of the oral mucosa, staining of teeth and gingiva, and trismus are major symptoms. Major constituents of betel quid are arecoline from betel nuts and copper, which are responsible for fibroblast dysfunction and fibrosis. A variety of extracellular and intracellular signaling pathways might be involved. Treatment of OSF is difficult, as not many large, randomized controlled trials have been conducted. The principal actions of drug therapy include antifibrotic, anti-inflammatory, and antioxygen radical mechanisms. Potential new drugs are on the horizon. Surgery may be necessary in advanced cases of trismus. Prevention is most important, as no healing can be achieved with available treatments. Dove Medical Press 2015-04-13 /pmc/articles/PMC4401336/ /pubmed/25914554 http://dx.doi.org/10.2147/CCID.S80576 Text en © 2015 Wollina et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Wollina, Uwe Verma, Shyam B Ali, Fareedi Mukram Patil, Kishor Oral submucous fibrosis: an update |
title | Oral submucous fibrosis: an update |
title_full | Oral submucous fibrosis: an update |
title_fullStr | Oral submucous fibrosis: an update |
title_full_unstemmed | Oral submucous fibrosis: an update |
title_short | Oral submucous fibrosis: an update |
title_sort | oral submucous fibrosis: an update |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401336/ https://www.ncbi.nlm.nih.gov/pubmed/25914554 http://dx.doi.org/10.2147/CCID.S80576 |
work_keys_str_mv | AT wollinauwe oralsubmucousfibrosisanupdate AT vermashyamb oralsubmucousfibrosisanupdate AT alifareedimukram oralsubmucousfibrosisanupdate AT patilkishor oralsubmucousfibrosisanupdate |